Scholarlink

<p>FKBP51 is a multifunctional immunophilin that regulates key cellular pathways, including NF-κB signaling, AKT activation, and steroid receptor trafficking. Alternative splicing of the FKBP5 gene generates a shorter isoform, FKBP51s, lacking the C-terminal TPR domain mediating protein‒protein interactions. Previous studies support the hypothesis that splicing of the FKBP5 gene underpins the mechanisms crucial for establishing control over T lymphocyte expansion and that the balance between the canonical and spliced isoforms could be pivotal in the immune system’s capacity to finely tune the intensity and span of the immune response.</p><p>To investigate the impact of FKBP51 splicing, we generated a knock-in mouse model (hu<i>FKBP5</i>) expressing only the full-length human FKBP51 isoform, thereby ablating all splice variants. While the heterozygous animals were viable and fertile, the homozygous hu<i>FKBP5</i><sup>+/+</sup> mice presented a sub-Mendelian frequency, infertility, and widespread lymphoid infiltrates, suggesting impaired immune homeostasis. In a syngeneic melanoma model, hu<i>FKBP5</i><sup>+/-</sup> mice presented a potent antitumor response characterized by reduced tumor growth, increased lymphocyte infiltration, elevated levels of cytotoxic markers (perforin, Bax, cleaved caspase-3 and -7, gasderminE), and the upregulation of CCR7 and CXCR5 on tumor-infiltrating lymphocytes. By employing synthetic mRNAs, we demonstrated that FKBP51 retains functional equivalence across species in driving lymphocyte activation. The FKBP51s isoform functions as a dominant-negative regulator of murine lymphocyte effector functions. These findings support the conclusion that inhibiting FKBP51 splicing preserves lymphocyte effector activity and prevents their transition toward resting or exhausted states. In the tumor context, this translates into a heightened antitumor immune response and a reduction in tumor tolerance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FKBP5 isoforms shape immune pathways related to tumor tolerance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Simona Romano,
  • Laura Marrone,
  • Gennaro Acanfora,
  • Valeria Di Giacomo,
  • Marialuisa Alessandra Vecchione,
  • Elena Vigliar,
  • Antonino Iaccarino,
  • Nicola Russo,
  • Emanuele Sasso,
  • Guendalina Froechlich,
  • Massimiliano Cacace,
  • Chiara Malasomma,
  • Rosetta Abate,
  • Simona Caggiano,
  • Federica Aracri,
  • Yichuan Xiao,
  • Giancarlo Troncone,
  • Tommaso Russo,
  • Maria Fiammetta Romano

摘要

FKBP51 is a multifunctional immunophilin that regulates key cellular pathways, including NF-κB signaling, AKT activation, and steroid receptor trafficking. Alternative splicing of the FKBP5 gene generates a shorter isoform, FKBP51s, lacking the C-terminal TPR domain mediating protein‒protein interactions. Previous studies support the hypothesis that splicing of the FKBP5 gene underpins the mechanisms crucial for establishing control over T lymphocyte expansion and that the balance between the canonical and spliced isoforms could be pivotal in the immune system’s capacity to finely tune the intensity and span of the immune response.

To investigate the impact of FKBP51 splicing, we generated a knock-in mouse model (huFKBP5) expressing only the full-length human FKBP51 isoform, thereby ablating all splice variants. While the heterozygous animals were viable and fertile, the homozygous huFKBP5+/+ mice presented a sub-Mendelian frequency, infertility, and widespread lymphoid infiltrates, suggesting impaired immune homeostasis. In a syngeneic melanoma model, huFKBP5+/- mice presented a potent antitumor response characterized by reduced tumor growth, increased lymphocyte infiltration, elevated levels of cytotoxic markers (perforin, Bax, cleaved caspase-3 and -7, gasderminE), and the upregulation of CCR7 and CXCR5 on tumor-infiltrating lymphocytes. By employing synthetic mRNAs, we demonstrated that FKBP51 retains functional equivalence across species in driving lymphocyte activation. The FKBP51s isoform functions as a dominant-negative regulator of murine lymphocyte effector functions. These findings support the conclusion that inhibiting FKBP51 splicing preserves lymphocyte effector activity and prevents their transition toward resting or exhausted states. In the tumor context, this translates into a heightened antitumor immune response and a reduction in tumor tolerance.